TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

It's been a good week for TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders, because the company has just released ...

TD Cowen has recently initiated TG Therapeutics Inc common stock (TGTX) stock to Buy rating, as announced on October 29, 2024, according to Finviz. Earlier, on August 2, 2023, Goldman had raised the ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Third Quarter 2024 Results Key Financial Results Revenue: US$83.9m (down 49% from ...

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price ...

TG Therapeutics Inc (TGTX) reports over 230% year-over-year revenue growth, raises full-year guidance, and outlines future ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics stock crashed Monday after missing profit expectations, though sales of its multiple sclerosis treatment beat forecasts.